Engelsk titel: Pharmacotherapy for obesity
Läs online
Författare:
Bruun, Jens Meldgaard
Email: jensbruu@rm.dk
Språk: Dan
Antal referenser: 28
Dokumenttyp:
Översikt
UI-nummer: 17017289
Sammanfattning
Obesity is a chronic condition, which is why pharmacotherapy can be considered, if lifestyle modification (hypocaloric diet/exercise)
does not result in a weight loss of at least 5%. Pharmacotherapy is indicated, if an individual has a BMI > 30 kg/m2 or a BMI > 27 kg/m2 and
concomitant disease (e.g. Type 2 diabetes), and can be liraglutide (3 mg) or orlistat (120 mg/60 mg). Choice of treatment must be based on
patient preferences and clinical situation, side effects, contraindications and financial considerations. Weight loss of < 5% (about 4-5 kg) after
12 weeks should lead to cessation of the treatment.